Business Description
PharmaCielo Ltd
NAICS : 325410
SIC : 3741
ISIN : CA00035L1022
Share Class Description:
TSXV:PCLO: Ordinary SharesTotal Employee Number:
268Description
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | -1.79 | |||||
Debt-to-Equity | -1.21 | |||||
Debt-to-EBITDA | 94.18 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -37.36 | |||||
Beneish M-Score | -6.9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -25.3 | |||||
3-Year EBITDA Growth Rate | 41.1 | |||||
3-Year EPS without NRI Growth Rate | 40.8 | |||||
3-Year FCF Growth Rate | 49.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.65 | |||||
9-Day RSI | 36.06 | |||||
14-Day RSI | 42.05 | |||||
3-1 Month Momentum % | 100 | |||||
6-1 Month Momentum % | -14.29 | |||||
12-1 Month Momentum % | 50 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.15 | |||||
Quick Ratio | 0.08 | |||||
Cash Ratio | 0.01 | |||||
Days Inventory | 407.77 | |||||
Days Sales Outstanding | 74.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.8 | |||||
Shareholder Yield % | 9.12 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 24.53 | |||||
Operating Margin % | -161.06 | |||||
Net Margin % | -125.41 | |||||
EBITDA Margin % | 10.89 | |||||
FCF Margin % | -48.51 | |||||
OCF Margin % | -48.51 | |||||
ROA % | -16.99 | |||||
ROIC % | -10.21 | |||||
3-Year ROIIC % | 1154.48 | |||||
ROC (Joel Greenblatt) % | -4.57 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.5 | |||||
EV-to-EBIT | -64.92 | |||||
EV-to-EBITDA | 154.43 | |||||
EV-to-Revenue | 16.82 | |||||
EV-to-Forward-Revenue | 6.41 | |||||
EV-to-FCF | -34.67 | |||||
Price-to-GF-Value | 0.43 | |||||
Earnings Yield (Greenblatt) % | -1.54 | |||||
FCF Yield % | -7.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmaCielo Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 1.818 | ||
| EPS (TTM) (C$) | -0.012 | ||
| Beta | -0.5346 | ||
| 3-Year Sharpe Ratio | 0.05 | ||
| 3-Year Sortino Ratio | 0.09 | ||
| Volatility % | 142.34 | ||
| 14-Day RSI | 42.05 | ||
| 14-Day ATR (C$) | 0.007359 | ||
| 20-Day SMA (C$) | 0.07475 | ||
| 12-1 Month Momentum % | 50 | ||
| 52-Week Range (C$) | 0.035 - 0.165 | ||
| Shares Outstanding (Mil) | 187.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaCielo Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaCielo Ltd Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-11-16 | In 125 days | ||
| First quarter earnings results for 2027 | 2026-10-23 | In 101 days | ||
| Fourth quarter earnings results for 2026 | 2026-10-06 | In 84 days | ||
| General meeting for 2025 | 2026-04-02 11:00 | 0.06 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-03-02 | 0.05 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-12-05 | 0.05 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-10-24 | 0.05 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-10-06 | 0.05 (+0.00%) | ||
| Annual report for 2025 | 2025-10-01 | 0.05 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-02-28 | 0.07 (-12.50%) |
Show
Entries
PharmaCielo Ltd Frequently Asked Questions
What is PharmaCielo Ltd(TSXV:PCLO)'s stock price today?
The current price of TSXV:PCLO is C$0.07. The 52 week high of TSXV:PCLO is C$0.17 and 52 week low is C$0.04.
When is next earnings date of PharmaCielo Ltd(TSXV:PCLO)?
The next earnings date of PharmaCielo Ltd(TSXV:PCLO) is 2026-10-06 Est..
Does PharmaCielo Ltd(TSXV:PCLO) pay dividends? If so, how much?
PharmaCielo Ltd(TSXV:PCLO) does not pay dividend.
Press Release
Articles on PharmaCielo Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers